Description

BIM-23190, a somatostatin analog, a selective SSTR2 and SSTR5 agonist, exhibits Ki values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 can be used in the study for cancer and acromegaly[1][3].—Cancer-programmed cell death–C57H79N13O12S2—-[1]I Shimon, et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest. 1997 Nov 1;100(9):2386-92.|[2]Federica Barbieri, et al. Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice. Am J Physiol Endocrinol Metab. 2009 Nov;297(5):E1078-88.|[3]T J Gillespie, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther. 1998 Apr;285(1):95-104.–182153-96-4–1202.45—-O=C(N[C@H](C(N[C@H](C(N1)=O)CC)=O)CCCCN)[C@H](NC([C@@H](NC([C@H](CSSC[C@H]1C(N[C@H](C(N)=O)[C@H](O)C)=O)NC([C@H](NC(CN(CC2)CCN2CCO)=O)CC3=CC=CC=C3)=O)=O)CC(C=C4)=CC=C4O)=O)CC5=CNC6=CC=CC=C56–Cancer–10 mM in DMSO–Somatostatin Receptor–SSTR2;SSTR5–GPCR/G Protein;Neuronal Signaling–Peptides